These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
322 related items for PubMed ID: 27884092
1. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. Liu X, Deng T, Guo X, Guo Y, Wang L, Zhang J, Xia Z, Zhang Q, Xue K, Cao J, Shi J, Hong X. Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092 [Abstract] [Full Text] [Related]
2. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS. Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):79-85. PubMed ID: 19647953 [Abstract] [Full Text] [Related]
3. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy. Goldschmidt N, Kleinstern G, Orevi M, Paltiel O, Ben-Yehuda D, Gural A, Libster D, Lavie D, Gatt ME. Cancer Chemother Pharmacol; 2016 May 01; 77(5):1053-60. PubMed ID: 27056383 [Abstract] [Full Text] [Related]
4. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. Malenda A, Kołkowska-Leśniak A, Puła B, Długosz-Danecka M, Chełstowska M, Końska A, Giza A, Lech-Marańda E, Jurczak W, Warzocha K. Eur J Haematol; 2020 Jan 01; 104(1):59-66. PubMed ID: 31606909 [Abstract] [Full Text] [Related]
5. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. Shin HJ, Yoon DH, Lee HS, Oh SY, Yang DH, Kang HJ, Chong SY, Park Y, Do Y, Lim SN, Jo JC, Lee WS, Chung JS, Consortium for Improving Survival of Lymphoma. Exp Hematol; 2016 Jan 01; 44(1):3-13. PubMed ID: 26325332 [Abstract] [Full Text] [Related]
6. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Pejša V, Prka Ž, Lucijanić M, Mitrović Z, Piršić M, Jakšić O, Ajduković R, Kušec R. Croat Med J; 2017 Feb 28; 58(1):40-48. PubMed ID: 28252874 [Abstract] [Full Text] [Related]
7. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. Strüßmann T, Fritsch K, Baumgarten A, Fietz T, Engelhardt M, Mertelsmann R, Ihorst G, Duyster J, Finke J, Marks R. Br J Haematol; 2017 Sep 28; 178(6):927-935. PubMed ID: 28643323 [Abstract] [Full Text] [Related]
8. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H, Kahl BS, Advani RH, Horning SJ. Br J Haematol; 2015 Sep 28; 170(5):679-86. PubMed ID: 25974212 [Abstract] [Full Text] [Related]
9. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. Lisenko K, Dingeldein G, Cremer M, Kriegsmann M, Ho AD, Rieger M, Witzens-Harig M. BMC Cancer; 2017 May 22; 17(1):359. PubMed ID: 28532396 [Abstract] [Full Text] [Related]
10. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS. Leuk Lymphoma; 2010 May 22; 51(5):789-96. PubMed ID: 20367136 [Abstract] [Full Text] [Related]
11. Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-lymphoma. Avilés A, Neri N, Fernández R, Huerta-Guzmán J, Nambo MJ. Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):1227-31. PubMed ID: 22172907 [Abstract] [Full Text] [Related]
12. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. Kumar A, Lunning MA, Zhang Z, Migliacci JC, Moskowitz CH, Zelenetz AD. Br J Haematol; 2015 Dec 15; 171(5):776-83. PubMed ID: 26456939 [Abstract] [Full Text] [Related]
13. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO). Eur J Haematol; 2008 Mar 15; 80(3):227-35. PubMed ID: 18088400 [Abstract] [Full Text] [Related]
14. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. De Sanctis V, Finolezzi E, Osti MF, Grapulin L, Alfò M, Pescarmona E, Berardi F, Natalino F, Moleti ML, Di Rocco A, Enrici RM, Foà R, Martelli M. Int J Radiat Oncol Biol Phys; 2008 Nov 15; 72(4):1154-60. PubMed ID: 18472357 [Abstract] [Full Text] [Related]
15. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Int J Radiat Oncol Biol Phys; 2015 May 01; 92(1):113-21. PubMed ID: 25863759 [Abstract] [Full Text] [Related]
16. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M. Clin Lymphoma Myeloma; 2009 Oct 01; 9(5):381-5. PubMed ID: 19858058 [Abstract] [Full Text] [Related]
17. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E, Barbarano L, Nosari AM, Morra E. Bone Marrow Transplant; 2002 Mar 01; 29(6):473-7. PubMed ID: 11960265 [Abstract] [Full Text] [Related]
18. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z. Ann Hematol; 2012 Jun 01; 91(6):837-45. PubMed ID: 22160255 [Abstract] [Full Text] [Related]
19. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Papajik T, Raida L, Faber E, Vondrakova J, Prochazka V, Kubova Z, Skoumalova I, Jarosova M, M LK, Paucek B, Myslivecek M, Neoral C, Oral I, Jarkovsky J, Dusek L, Indrak K. Neoplasma; 2008 Jun 01; 55(3):215-21. PubMed ID: 18348654 [Abstract] [Full Text] [Related]
20. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, Tomita A, Sasaki M, Takizawa J, Mitani K, Igarashi T, Maeda Y, Fukuhara N, Ishida F, Niitsu N, Ohmachi K, Takasaki H, Nakamura N, Kinoshita T, Nakamura S, Ogura M. Haematologica; 2014 Dec 01; 99(12):1817-25. PubMed ID: 25216682 [Abstract] [Full Text] [Related] Page: [Next] [New Search]